证券代码：605033 证券简称：美邦股份 公告编号：2026-005 关于公司股票交易风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 陕西美邦药业集团股份有限公司（以下简称"公司"或"本公司"）股票于 2026 年 2 月 10 日、2 月 11 日、2 月 12 日连续 3 个交易日收盘价格涨幅偏离值 累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异 常波动情形。公司于 2026 年 2 月 13 日披露了《陕西美邦药业集团股份有限公司 股票交易异常波动公告》（公告编号：2026-004）。2026 年 2 月 13 日，公司股票 再次涨停，近期公司股票价格波动幅度较大。 陕西美邦药业集团股份有限公司 公司于 2025 年 10 月 29 日披露了《陕西美邦药业集团股份有限公司 2025 年第三季度报告》，公司 2025 年前三季度实现营业收入 6.09 亿元，同比下降 2.23%；实现归属于上市公司股东的净利润 3619.61 万元，同比下降 16.36%（以 ...

Group 1 - The core point of the article is that Meibang Co., Ltd. experienced significant stock price fluctuations, with a cumulative increase of over 20% in closing prices over three consecutive trading days from February 10 to 12, 2026, and a further limit-up on February 13, resulting in a total increase of 33.10% during this period [1] - The company's latest rolling price-to-earnings ratio stands at 130.16, which is significantly higher than the industry average of 31.99 [1] - For the first three quarters of 2025, the company reported revenue of 609 million yuan, a year-on-year decrease of 2.23%, and a net profit of 36.1961 million yuan, reflecting a year-on-year decline of 16.36% [1]

美邦股份涨停走出3连板，3天累计涨幅达33.1%。 ...

Group 1 - The core point of the article is that Meibang Co., Ltd. announced a significant stock price fluctuation, with a cumulative increase of over 20% in closing prices over three consecutive trading days from February 10 to February 12, 2026 [1] - The company confirmed that its production and operational activities are normal and that there have been no significant changes in the external environment [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 陕西美邦药业集团股份有限公司（以下简称"公司"或"本公司"）股票于 2026 年 2 月 10 日、2 月 11 日、2 月 12 日连续 3 个交易日收盘价格涨幅偏离值 累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异 常波动情形。 经公司自查，并向控股股东及实际控制人核实，截至本公告披露日，除 本公司已披露事项外，不存在应披露而未披露的重大信息。 公司敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 证券代码：605033 证券简称：美邦股份 公告编号：2026-004 陕西美邦药业集团股份有限公司 股票交易异常波动公告 经公司自查，公司未发现存在对公司股票交易价格可能产生重大影响的媒体 报道及市场传闻，也未涉及市场热点概念。 （四）其他股价敏感信息 一、股票交易异常波动的具体情况 公司股票交易于 2026 年 2 月 10 日、2 月 11 日、2 月 12 日连续 3 个交易日 收盘价格涨幅偏离值累计超过 20%，根 ...

《关于陕西美邦药业集团股份有限公司股票交易异常波动问询函》的 回函 陕西美邦药业集团股份有限公司: 贵公司发出的《关于陕西美邦药业集团股份有限公司股票交易异常波动问询 函》已收悉，经认真自查核实，现将有关问题回复如下： 一、截至目前，本人不存在涉及贵公司的应披露而未披露的重大信息； 二、截至目前,本人不存在处于筹划阶段的涉及贵公司的重大事项,包括但 不限于重大资产重组、股票发行、收购、债务重组、业务重组、资产剥离、资产 注入、股份回购、股权激励、破产重整、重大业务合作、引进战略投资者等重大 事项; 三、本次股票交易异常波动期间，本人不存在买卖贵公司股票的情形。 特此函复。 (本页以下无正文) (本业无正文，为《<关于陕西美邦药业集团股份有限公司股票交易异常波动何 询函>的回函》之签章页） t 控股股东、实际担制人： ^_VX/ 回家 陕西美邦药业集团股份有限公司: 贵公司发出的《关于陕西美邦药业集团股份有限公司股票交易异常波动间询 函》已收悉，经认真自查核实,现将有关问题回复如下: 一、截至目前，本人不存在涉及贵公司的应披露而未披露的重大信息； 二、截至目前，本人不存在处于筹划阶段的涉及贵公司的重大事项，包括 ...

美邦股份公告称，公司股票于2026年2月10日、2月11日、2月12日连续3个交易日收盘价格涨幅偏离值累 计超过20%，属股票交易异常波动情形。经自查，公司生产经营正常，外部环境无重大变化，除已披露 事项外，不存在应披露而未披露的重大信息。未发现对股价有重大影响的媒体报道及市场传闻，未涉及 市场热点概念。公司董事、高管、控股股东及实控人在此期间无买卖公司股票情况。公司提醒投资者注 意交易风险，理性投资。 ...

Core Viewpoint - The A-share market saw a significant rally in the chemical sector, with multiple stocks experiencing substantial gains on February 12, indicating strong investor interest and potential growth in this industry [1]. Group 1: Stock Performance - Changhua Chemical (301518) rose by 10.57%, with a total market capitalization of 65.46 billion and a year-to-date increase of 26.51% [2]. - Meibang Shares (605033) increased by 10.00%, with a market cap of 35.23 billion and a year-to-date rise of 29.78% [2]. - Jianxin Shares (300107) saw a gain of 9.80%, with a market value of 49.19 billion and a year-to-date increase of 28.15% [2]. - Weike Technology (301196) grew by 8.98%, with a market capitalization of 108 billion and a year-to-date increase of 7.65% [2]. - Kexin Source (300731) increased by 6.92%, with a market cap of 83.04 billion and a year-to-date rise of 16.83% [2]. - Huide Technology (603192) rose by 5.80%, with a market value of 39.31 billion and a year-to-date increase of 5.68% [2]. - New Jinlu (000510) saw a gain of 5.58%, with a market capitalization of 113 billion and a year-to-date increase of 50.26% [2]. - Zhenhua Shares (603067) increased by 5.38%, with a market cap of 263 billion and a year-to-date rise of 28.57% [2]. - ST Yatai (000691) rose by 5.02%, with a market value of 41.56 billion and a year-to-date increase of 21.56% [2]. - Guangkang Biochemical (300804) increased by 4.00%, with a market cap of 33.87 billion and a year-to-date rise of 30.77% [2]. - Hangjin Technology (000818) saw a gain of 4.00%, with a market capitalization of 163 billion and a year-to-date increase of 28.03% [2]. - Hongda Shares (600331) rose by 3.98%, with a market value of 463 billion and a year-to-date increase of 36.90% [2]. - Demei Chemical (002054) increased by 3.31%, with a market cap of 52.65 billion and a year-to-date rise of 47.97% [2]. - Huangma Technology (603181) saw a gain of 3.17%, with a market capitalization of 99.49 billion and a year-to-date increase of 18.26% [2]. - Runmu Materials (300727) rose by 3.14%, with a market value of 65.73 billion and a year-to-date increase of 2.38% [2]. - Litong Technology (920225) increased by 3.09%, with a market cap of 38.08 billion and a year-to-date decrease of 6.40% [2].

Core Viewpoint - The A-share market has seen a significant rally in the chemical sector, with multiple companies experiencing substantial gains in their stock prices [1] Group 1: Company Performance - Changhua Chemical has increased by over 10% [1] - Meibang Co. has reached a 10% limit up [1] - Jianxin Co. has risen by over 9% [1] - Weike Technology has gained over 8% [1] - Kexin Innovation Source has increased by over 6% [1] - Huide Technology, Xinjin Road, and Zhenhua Co. have all risen by over 5% [1]

Group 1 - The company Meibang Co., Ltd. announced that as of the date of the announcement, the total amount of guarantees provided for its wholly-owned subsidiaries is 800 million yuan, which accounts for 71.13% of the company's audited net assets for the year 2024 [1] - As of the date of the announcement, the total balance of guarantees actually provided by the company for its wholly-owned subsidiaries within the scope of consolidated financial statements is 287 million yuan, representing 25.52% of the company's audited net assets for the year 2024 [1] Group 2 - The central bank, which has been the largest buyer of gold for two consecutive years, announced plans to purchase an additional 150 tons of gold, aiming to accumulate a total of 700 tons [1]